Effect of patient-derived stem-cells (Rigenera autologous micrografts [AMT]) on surgical hair restoration outcomes in patient with hair loss undergoing Follicular Unit Transplant (FUT) hair transplant

Not Applicable

• Conditions: Androgenic alopecia; Metabolic and Endocrine - Other endocrine disorders; Skin - Dermatological conditions

• Registration Number: ACTRN12624000763549
• Lead Sponsor: Dr Adam Ellerby

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-06-21
• Last Update Posted: 8 July 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Forty patients aged over 25 undergoing FUT hair transplant for androgenetic alopecia (AGA).
Patients selected based on their need for frontal region transplant
Frontal recipient area must have advanced AGA
Medications - Every patient should be stabilised on hair loss medications (ie slow progression or cessation of hair loss for >6 months using standard medical therapies)

Exclusion Criteria

Non-androgenic cause for alopecia - autoimmune, scaring, thyroid, iron and vitamin D deficiencies.
Previous hair transplant surgery within past 18 months
Other regenerative treatments within past 12 months - Rigenera, Platelet rich plasma (PRP), Platelet rich fibrin (PRF)
Inter-current systemic illness or scalp disease - Human immunodeficiency virus (HIV), Hepatitis, cancer, haematological disease, fungal scalp, dermatitis
Interstate or out of area patients due to in-person follow up requirements - New South Wales (NSW) patients only

Study & Design

• Study Type: Interventional
• Study Design: Not specified